Synthetic Biologics (SYN) Trading Down 8.3%

Synthetic Biologics Inc (NYSEAMERICAN:SYN) shares fell 8.3% during trading on Friday . The stock traded as low as $0.11 and last traded at $0.11. 785,581 shares were traded during mid-day trading, an increase of 2% from the average session volume of 767,227 shares. The stock had previously closed at $0.12.

Several brokerages recently commented on SYN. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Synthetic Biologics in a research report on Thursday. Griffin Securities cut Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th. Finally, Zacks Investment Research cut Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, April 25th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. Synthetic Biologics currently has an average rating of “Hold” and a consensus target price of $21.88.

Shares of Synthetic Biologics are going to reverse split on the morning of Monday, August 13th. The 1-35 reverse split was announced on Wednesday, August 1st. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, August 10th.

Synthetic Biologics (NYSEAMERICAN:SYN) last issued its earnings results on Wednesday, August 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.40) by $0.35.

A hedge fund recently raised its stake in Synthetic Biologics stock. Blair William & Co. IL grew its stake in shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) by 14.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,980,857 shares of the company’s stock after purchasing an additional 255,096 shares during the quarter. Blair William & Co. IL owned about 1.54% of Synthetic Biologics worth $631,000 at the end of the most recent quarter.

About Synthetic Biologics

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Featured Story: Market Capitalization

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.

Leave a Reply